上海君实生物医药科技股份有限公司 自愿披露关于拓益■新增适应症和君适达■纳入国家医保目录的公告

Core Viewpoint - Shanghai Junshi Biosciences Co., Ltd. has successfully included two of its products, Toripalimab Injection (brand name: Tuoyi) and Engrelistat Injection (brand name: Junshida), in the National Medical Insurance Catalog (2025) under Category B, effective from January 1, 2026 [1][2]. Group 1: Product Information - Toripalimab Injection is the first domestically approved PD-1 monoclonal antibody in China, with 12 indications approved for listing in the National Medical Insurance Catalog, including treatments for renal cancer, triple-negative breast cancer, and melanoma [2][4]. - Engrelistat Injection is a domestically developed PCSK9-targeting drug, newly included in the National Medical Insurance Catalog, specifically for patients intolerant to statins [5][6]. Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Catalog reflects the recognition of their clinical value and innovation by the National Healthcare Security Administration, which supports local innovative pharmaceutical companies [6]. - The listing of all commercialized products in the National Medical Insurance Catalog is expected to enhance affordability and accessibility for patients, thereby promoting market expansion and increasing sales scale for the company [6].